Status:
WITHDRAWN
Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection
Lead Sponsor:
University Hospital, Limoges
Conditions:
COVID-19 Infection
Sars-cov-2
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The current sars-cov-2 epidemic is responsible for severe respiratory infections leading to end-of-life situations. Dexmedetomidine may be indicated in mild to moderate sedation in palliative patient...
Eligibility Criteria
Inclusion
- Major patient
- Relating to palliative care
- With sars-cov-2 infection
- Requiring light to moderate sedation corresponding to a RASS score of -1 to -3
Exclusion
- Pregnant, lactating woman.
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the summary of product characteristics
- Advanced heart block (level 2 or 3) unless a pacemaker.
- Uncontrolled hypotension.
- Acute cerebrovascular pathologies.
- Use of other sedative drugs
Key Trial Info
Start Date :
April 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 20 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04350086
Start Date
April 20 2020
End Date
November 20 2020
Last Update
September 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Limoges, France, 87200